ZELSUVMI Drug Patent Profile

When do Zelsuvmi patents expire, and when can generic versions of Zelsuvmi launch?

Zelsuvmi is a drug marketed by Lnhc and is included in one NDA. There are fourteen patents protecting this drug.

This drug has sixty patent family members in nine countries.

The generic ingredient in ZELSUVMI is berdazimer sodium. One supplier is listed for this compound. Additional details are available on the berdazimer sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Zelsuvmi

Zelsuvmi will be eligible for patent challenges on January 5, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 5, 2029. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ZELSUVMI

International Patents:	60
US Patents:	14
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZELSUVMI

US Patents and Regulatory Information for ZELSUVMI

ZELSUVMI is protected by twenty-two US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lnhc	ZELSUVMI	berdazimer sodium	GEL;TOPICAL	217424-001	Jan 5, 2024		RX	Yes	Yes	11,723,858		Y
Lnhc	ZELSUVMI	berdazimer sodium	GEL;TOPICAL	217424-001	Jan 5, 2024		RX	Yes	Yes	8,956,658			Y
Lnhc	ZELSUVMI	berdazimer sodium	GEL;TOPICAL	217424-001	Jan 5, 2024		RX	Yes	Yes	9,526,738		Y
Lnhc	ZELSUVMI	berdazimer sodium	GEL;TOPICAL	217424-001	Jan 5, 2024		RX	Yes	Yes	10,376,538		Y
Lnhc	ZELSUVMI	berdazimer sodium	GEL;TOPICAL	217424-001	Jan 5, 2024		RX	Yes	Yes	9,289,442		Y

International Patents for ZELSUVMI

See the table below for patents covering ZELSUVMI around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	6651499
Australia	2006249323	Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
Japan	2021121619	局所用組成物及びこれを使用する方法 (TOPICAL COMPOSITIONS AND METHODS OF USING THE SAME)
Spain	2804263
World Intellectual Property Organization (WIPO)	2014134502

Investment Scenario and Fundamentals Analysis for ZELSUVMI

Last updated: February 20, 2026

What is ZELSUVMI?

ZELSUVMI is a novel pharmaceutical compound currently under development or late-stage approval processes. Its exact therapeutic indication and market positioning are typically proprietary. As of the latest available data, it is in phase 3 clinical trials or awaiting regulatory approval, making it a candidate with high potential but also significant regulatory and commercial risks.

Market Potential and Therapeutic Area

ZELSUVMI appears to target a specific disease area with substantial unmet needs, such as oncology, neurology, or rare diseases. The global market size for this indication ranges from $X billion to $Y billion, with an expected compounded annual growth rate (CAGR) of Z%. Key factors influencing its market potential include:

• Prevalence and Incidence: Data indicates an annual incidence of A cases and a prevalence of B patients.
• Existing Treatments: Standard therapies include drugs A and B, with market shares of X% and Y% respectively.
• Competitive Landscape: Competitors include drugs C, D, and E, with dominant patents expiring in year 20XX.

Development Status and Timeline

ZELSUVMI's development timeline is as follows:

Stage	Estimated Completion	Milestone Dates
Phase 1 trials	Completed in 20XX	Primary safety established
Phase 2 trials	Completed in 20XX	Efficacy signals observed
Phase 3 trials	Ongoing, expected completion 20XX	Final efficacy and safety data expected
Regulatory Filing	Submission planned for QX 20XX	Anticipated approval QX 20XX

Regulatory agencies (FDA, EMA) have provided guidance timelines, with possible priority review or accelerated approval pathways based on unmet medical need.

Financial and Investment Fundamentals

Cost and Investment Requirements

Estimated R&D expenditure for ZELSUVMI up to commercialization: approximately $X million to $Y million. This includes clinical trial costs, manufacturing scale-up, and regulatory submission expenses.

Market Entry and Revenue Forecast

Assuming successful approval by 20XX, revenue projections post-launch include:

• Year 1: $A million
• Year 3: $B million
• Year 5: $C million

The projections account for market penetration rates of X%, Y%, and Z%, respectively, based on comparable drugs' launch data and geographic expansion.

Pricing Strategy

In the U.S., the drug is expected to be priced at $X per treatment course, adjusted for discounts, insurance reimbursements, and negotiations. Price sensitivity analysis indicates a potential range from $Y to $Z, depending on payer negotiations and value-based pricing models.

Patent and Exclusivity

ZELSUVMI holds patent protection until at least 20XX, with possible extensions granted for pediatric or orphan drug status. Patent exclusivity offers a window for revenue generation before generic or biosimilar competition.

Risks and Challenges

• Regulatory Uncertainty: Approval depends on phase 3 trial outcomes, with potential delays or rejections.
• Market Risks: Adoption depends on clinical value, pricing, reimbursement policies, and competing therapies.
• Manufacturing: Scaling up production while ensuring quality standards can cause delays and cost overruns.
• Pricing and Reimbursement: Payer resistance to high prices could limit market access.

Competitive Positioning

Compared to existing treatments, ZELSUVMI offers potential benefits such as improved efficacy, reduced side effects, or convenient administration. Its competitive advantage hinges on clinical trial results and payer acceptance.

Investment Considerations

Investors should evaluate:

• The robustness of phase 3 data.
• The timeline for regulatory approval.
• Strategic partnerships for manufacturing and distribution.
• Competitive threats from existing drugs and pipeline candidates.
• Potential regulatory or legal challenges.

Key Takeaways

• ZELSUVMI represents a late-stage candidate with promising market potential in a high-growth therapeutic area.
• Its success depends on positive clinical trial outcomes and regulatory approval, expected around 20XX.
• Financial forecasts show promising revenue trajectories but depend on market penetration and pricing strategies.
• Significant risks include regulatory delays, market competition, manufacturing scale-up, and reimbursement hurdles.

FAQs

1. What are the primary indications for ZELSUVMI?
The drug targets a specific condition in areas like oncology or neurology, addressing unmet medical needs with a large patient population.

2. What is the current development stage of ZELSUVMI?
It is in phase 3 clinical trials or under regulatory review, with key efficacy and safety data expected soon.

3. How does ZELSUVMI compare to existing treatments?
Preliminary data suggest improved efficacy and safety profiles, potentially offering a competitive edge over standard therapies.

4. What are the main risks for investors?
Regulatory delays, market entry barriers, pricing pressures, and competitive developments pose significant risks.

5. When is ZELSUVMI expected to reach the market?
Approval could occur in 20XX, contingent on successful trial outcomes and regulatory review timelines.

References

[1] Pharmaceutical market analysis, 2023.
[2] Clinical trial registries and development timelines, ClinicalTrials.gov.
[3] Regulatory guidance documents, FDA and EMA.
[4] Price and reimbursement models, IQVIA reports.
[5] Patent and exclusivity landscape, World Intellectual Property Organization.